SCHEMBL191333

SCHEMBL191333

CCOC(=O)Cc1csc(Nc2cc(Oc3cccc4ccccc34)ccn2)n1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.51
▸ ALDH1A1 P00352 5/20 0.51
▸ TDP1 Q9NUW8 1/20 0.51
▸ LTC4S Q16873 1/20 0.51
▸ KMT2A Q03164 3/20 0.50
▸ MEN1 O00255 2/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ LMNA P02545 4/20 0.48
▸ TP53 P04637 1/20 0.48
▸ NPC1 O15118 2/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ HTT P42858 2/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ GALR3 O60755 1/20 0.47
▸ GAA P10253 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL190981 0.82 GCK (0.39) KMT2AMEN1NPC1RAB9A
SCHEMBL190775 0.81 GCK (0.53) MAPTALDH1A1GAA
SCHEMBL191582 0.78 ALDH1A1 (0.57) MAPTALDH1A1TDP1KMT2AMEN1
SCHEMBL24101409 0.75 TDP1 (0.65) MAPTALDH1A1TDP1KMT2AMEN1
SCHEMBL191326 0.74 GCK (0.49) NPC1RAB9A
SCHEMBL2656946 0.73 SMN1; SMN2 (0.64) MAPTALDH1A1LTC4SKMT2AMEN1
SCHEMBL190732 0.72 GCK (0.47) —
SCHEMBL190204 0.71 GCK (0.44) MAPTALDH1A1KMT2AMEN1SMN1; SMN2
SCHEMBL192859 0.71 GCK (0.53) —
SCHEMBL3618130 0.71 ALDH1A1 (0.72) ALDH1A1LTC4SKMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1986645-B1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2012-01-04 — — EP disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 — — US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 — — US disclosed
EP-1986645-A1 GLUCOKINASE ACTIVATORS Array Biopharma, Inc. (US) 2008-11-05 — — EP disclosed
WO-2007089512-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2007-08-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247526-A1 GLUCOKINASE ACTIVATORS GCKR, GCK, GALK1 MAPT 4375/4885ALDH1A1 1869/4885TDP1 2864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback